Allergies:
Indications for: ORALAIR
Grass pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by a (+) skin test or in vitro testing for pollen-specific IgE antibodies. Not for immediate relief of allergic symptoms.
Adult Dosage:
Initiate 4 months before onset of grass pollen season and continue throughout season. Give 1st dose under physician supervision; observe ≥30mins for signs/symptoms of a severe allergic reaction; if tolerated, subsequent doses may be taken at home. ≥18–65yrs: 300 IR daily. Allow complete dissolution under the tongue before swallowing. Avoid food or beverage for 5mins after dosing.
Children Dosage:
<5yrs: not established. Initiate 4 months before onset of grass pollen season and continue throughout season. Give 1st dose under physician supervision; observe ≥30mins for signs/symptoms of a severe allergic reaction; if tolerated, subsequent doses may be taken at home. 5–17yrs: 100 IR daily on Day 1; 200 IR daily on Day 2, then 300 IR daily on Day 3 and thereafter. Allow complete dissolution under the tongue before swallowing. Avoid food or beverage for 5mins after dosing.
ORALAIR Contraindications:
Severe, unstable, or uncontrolled asthma. History of severe systemic allergic reaction or any local reaction to sublingual allergen immunotherapy. History of eosinophilic esophagitis.
Boxed Warning:
Severe allergic reactions.
ORALAIR Warnings/Precautions:
Risk of severe allergic reactions (eg, anaphylaxis, laryngopharyngeal edema); discontinue if occurs. Prescribe auto-injectable epinephrine for emergency use. Underlying conditions that may reduce survival of a serious allergic reaction after epinephrine use (eg, compromised lung function, unstable angina, recent MI, significant arrhythmia, uncontrolled hypertension). Moderate or severe asthma. Withhold therapy in acute asthma exacerbation; consider discontinuing if recurrent. Interrupt therapy for oral inflammation or wounds to allow complete healing. Increased risk of Oralair if treatment is initiated during grass pollen season. Elderly (>65yrs). Labor & delivery. Pregnancy. Nursing mothers.
ORALAIR Classification:
Allergen extract.
ORALAIR Interactions:
Concomitant other allergen immunotherapy: not studied. Avoid concomitant drugs that can potentiate or inhibit effects of epinephrine (eg, beta-blockers, alpha-blockers, ergot alkaloids, TCAs, levothyroxine, MAOIs, chlorpheniramine, diphenhydramine, [cardiac glycosides, diuretics; monitor for arrhythmias]).
Adverse Reactions:
Pruritus (oral, tongue, ear), throat irritation, mouth edema, cough, asthma, oropharyngeal pain, tonsillitis, oral paresthesia; severe systemic or local allergic reactions, eosinophilic esophagitis (discontinue if occurs).
Generic Drug Availability:
NO
How Supplied:
Blisters (100IR, 300IR)—3; (300IR)—30
